Women’s health from niche to mainstr...Women make up half of the world’s population. Finally, pharma companies and invetors are now beginning to pay more attention to female diseases. more ➔
Urgent need for medical data network acros... The COVID-19 pandemic is putting our health systems in Europe to the test. Capacity bottlenecks are becoming apparent, as are long-neglected investments in modern infrastructure. As the pandemic does … more ➔
“The COVID-19 impact was not all bad” Medical Cannabis – Last year, the European Cannabis Association was launched as industry interest group, but than the novel coronavirus pandemic changed everything. European Biotechnology spoke … more ➔
AMR – the silent pandemic that can stil... The COVID-19 pandemic is having a devastating effect on global health and an unprecedented impact on the economy. As the world struggles with the challenges brought on by this pandemic, the threat of … more ➔
Green carbon footprintIn September, Unilever announced a €1bn investment to improve the sustainability of its cleaning brands from the ground up. European Biotechnology spoke to Dr Neil Parry, R&D programme director … more ➔
The role of investors in addressing AMRAbigail Herron from Aviva Investors describes why AMR is a blind spot for investors and which action is needed to change it. more ➔
Protection in case of SPCs for pharmaceuti... SPCs offer up to five and a half years of additional protection after patent expiration for pharmaceuticals in order to compensate the patent holder’s inability to exploit their inventions while products … more ➔
Rentschler Biopharma expands U.S. footprin... Prior to Danish Genmab A/S’s recent licence option deal with AbbVie Inc, Rentschler Biopharma has extended its collaboration with Genmab. European Biotechnology spoke with Rentschler Biopharma SE’s … more ➔
The road to recovery goes via vaccines and...If reopening the economy after the prolonged shutdown was the end of the beginning, then the successful development of vaccines and therapeutic antibodies has the potential to be the beginning of the … more ➔
Product hopping Boon or Bane? Intellectual Property Providing access to medicines at affordable prices while maintaining incentives for the originators to invest into significant innovations is a balance that’s hard to find. Product … more ➔
